Accium BioSciences and Radiant Research Forge Strategic Co-Marketing Agreement.SEATTLE -- Accium BioSciences, Inc. (Accium), the first US company to develop a fully commercial analytical facility dedicated to Accelerator Mass Spectrometry accelerator mass spectrometry n. Mass spectroscopy in which a particle accelerator is used to disassociate molecules, ionize atoms, and accelerate the ions. (AMS AMS - Andrew Message System ) services, has forged a new strategic co-marketing agreement with Radiant Research, Inc. (Radiant). This agreement combines Accium's expertise in AMS-based study design and in-house analytical services with Radiant's state-of-the-art clinical trials facilities to provide pharmaceutical researchers with comprehensive Phase 0 (microdosing) and low radiation Phase I clinical services nationwide. "For the first time, this partnership provides our pharmaceutical sponsors with a one-stop solution for both the clinical and analytical components of early phase clinical trials," stated Ali Arjomand, Ph.D., President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of Accium BioSciences. "Radiant is leading the way in early phase clinical trial services in the US and Accium is pleased to be working with Radiant's experienced investigators, research professionals and business development teams." "Microdosing or Phase 0 studies enable our pharmaceutical sponsors the ability to obtain pharmacokinetic (PK) data earlier than conventional Phase I studies," stated Michael Lester, Chief Executive Officer of Radiant Research. "We are pleased to enter into this agreement with Accium and look forward to coupling Accium's AMS analytical services with clinical studies performed at sub-therapeutic doses." About Accium BioSciences Seattle, Washington  This page is protected from moves until disputes have been resolved on the .The reason for its protection is listed on the protection policy page. based Accium BioSciences, (pronounced "Axiom axiom, in mathematics and logic, general statement accepted without proof as the basis for logically deducing other statements (theorems). Examples of axioms used widely in mathematics are those related to equality (e.g. ") (www.acciumbio.com) is the first company to fully commercialize Accelerator Mass Spectrometry (AMS) analytical services in the US. Accium offers a full range of in-house services for Preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. , Phase 0 (microdosing) and Phase I clinical trials Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I . Accium makes available its in-house AMS analytical facility to highly qualified partners offering one-stop solutions that enable critical go/no-go decisions earlier in drug development. About Radiant Research Based in Bellevue, Washington Bellevue is a rapidly growing city in King County, Washington, U.S., across Lake Washington from Seattle. Long known as a suburb or satellite city of Seattle,[1] it is now categorized as an edge city or a boomburb. , Radiant Research (www.radiantresearch.com) is a comprehensive clinical research company that provides Phase 0-IV clinical drug development services to the biopharmaceutical and medical device industry. Radiant is comprised of more than 50 wholly-owned premier clinical research sites nationwide, employing over 1,000 research professionals exclusively focused on providing professional, high quality comprehensive clinical research services. In the past four years, Radiant has conducted more than 8,400 clinical trials across 18 therapeutic specialties. Radiant's client list includes every major pharmaceutical company and contract research organization and many biotechnology and medical device companies. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion